Related Experiment Video
Updated: May 9, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Adenoviral vectors for prodrug activation-based gene therapy for cancer
Joshua C Doloff, David J Waxman1
1Department of Cell and Molecular, Biology, Boston University, 5 Cummington Mall, Boston, MA 02215, USA. djw@bu.edu.
Abstract:
Cancer cell heterogeneity is a common feature - both between patients diagnosed with the same cancer and within an individual patient's tumor - and leads to widely different response rates to cancer therapies and the potential for the emergence of drug resistance. Diverse therapeutic approaches have been developed to combat the complexity of cancer, including individual treatment modalities designed to target tumor heterogeneity. This review discusses adenoviral vectors and how they can be modified to replicate in a cancer-specific manner and deliver therapeutic genes under multi-tiered regulation to target tumor heterogeneity, including heterogeneity associated with cancer stem cell-like subpopulations. Strategies that allow for combination of prodrug-activation gene therapy with a novel replication-conditional, heterogeneous tumor-targeting adenovirus are discussed, as are the benefits of using adenoviral vectors as tumor-targeting oncolytic vectors. While the anticancer activity of many adenoviral vectors has been well established in preclinical studies, only limited successes have been achieved in the clinic, indicating a need for further improvements in activity, specificity, tumor cell delivery and avoidance of immunogenicity.
Insights
This review explores using modified adenoviral vectors to target cancer cell heterogeneity and drug resistance. These vectors offer potential for improved cancer therapies by delivering genes specifically to tumors, including cancer stem cells.
Area of Science:
- Oncology
- Gene Therapy
- Virology
Background:
- Cancer cell heterogeneity complicates treatment, leading to varied responses and drug resistance.
- Existing therapies struggle to address the diverse nature of cancer cells within a tumor and between patients.
Purpose of the Study:
- To review the potential of modified adenoviral vectors for targeting cancer cell heterogeneity.
- To discuss strategies for enhancing adenoviral vector specificity and therapeutic gene delivery.
Main Methods:
- Discussion of adenoviral vector modifications for cancer-specific replication and gene delivery.
- Exploration of multi-tiered regulatory strategies to target tumor heterogeneity, including cancer stem cells.
- Review of combining prodrug-activation gene therapy with replication-conditional adenoviruses.
Main Results:
- Adenoviral vectors can be engineered for cancer-specific replication and targeted gene delivery.
- Combination strategies show promise for overcoming tumor heterogeneity and resistance.
- Preclinical studies demonstrate anticancer activity, but clinical success is limited.
Conclusions:
- Adenoviral vectors hold promise as oncolytic agents for targeting tumor heterogeneity.
- Further improvements in activity, specificity, delivery, and immunogenicity are needed for clinical translation.
Related Concept Videos
Gene Therapy
Gene Therapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Microorganisms in Medicine and Therapeutics
Mechanisms of Retrovirus-induced Cancers
